BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Wockhardt Launches Generic Version of Anti-Convulsant Drug Lamictal XR®


1/8/2013 10:21:22 AM

PARSIPPANY, N.J. and MUMBAI, India, Jan. 8, 2013 /PRNewswire/ -- Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamotrigine, which is used in treatment of epilepsy. Lamotrigine is the generic name for the brand Lamictal XR®, marketed in the United States by Glaxo SmithKline. Wockhardt is launching the product immediately and will be amongst the earliest generic versions of this product in the market.

(Logo: http://photos.prnewswire.com/prnh/20120615/NY25710LOGO )

"We are continuing our rapid momentum of 2012 into the New Year with this approval of Lamotrigine extended release tablets," said Dr. Habil Khorakiwala, Wockhardt Founder Chairman & Group CEO. "This is the sixth product with drug delivery technology that has received US FDA approval in the last 5 months, a continuing testimony to the R&D capabilities of Wockhardt," he said.

According to IMS Health, the total market for this product in the US is about $250 million. Lamotrigine is used extensively in management of epilepsy. Wockhardt already markets several other products in the United States in the CNS segment, especially anti-convulsant drugs.

In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. In many instances, Wockhardt, by virtue of being amongst the few players to market technically challenging products has reaped the advantage of being an early entrant.

Wockhardt will be manufacturing the extended-release tablets of Lamotrigine at its facility in Aurangabad, India. The technology for the extended release tablets was developed in-house.

About Wockhardt:

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 81% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 578 scientists, of whom 80 are doctorates. In all, Wockhardt has 169 Patents granted worldwide. In biotechnology research, it has built a competent 'Concept to Market' capabilities in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 7,900 people from 21 different nationalities.

Lamictal XR® is a registered trademark of Glaxo SmithKline.

Visit us at: www.wockhardt.com

Contact: Gopal Venkatesan, 973-257-4975

SOURCE Wockhardt USA



Read at BioSpace.com

Wockhardt
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES